Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures

Bone

Volumn 47, Issue 3, 2010, Pages 604-609

  Verdel, Bertha Maria ^a   Souverein, Patrick C ^a   Egberts, Toine C G ^a,b   van Staa, Tjeerd P ^a,c,d   Leufkens, Hubert G M ^a   de Vries, Frank ^a,c,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Antidepressants; Epidemiology; Fractures; Osteoporosis; Serotonin

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DIBENZEPIN; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; OPIPRAMOL; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; FEMALE; FRAGILITY FRACTURE; HOSPITAL ADMISSION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CASE-CONTROL STUDIES; DEPRESSION; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROTIC FRACTURES; RISK FACTORS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 77955843946     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.06.006     Document Type: Article

References (33)

1. Poole K.E., Compston J.E. Osteoporosis and its management. BMJ 2006, 333:1251-1256.
2. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
3. Johnell O., Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005, 16(Suppl 2):S3-S7.
4. Liu B., Anderson G., Mittmann N., To T., Axcell T., Shear N. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998, 35:1303-1307.
5. Ensrud K.E., Blackwell T., Mangione C.M., Bowman P.J., Bauer D.C., Schwartz A., et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003, 163:949-957.
6. Vestergaard P., Rejnmark L., Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 2006, 17:807-816.
7. Hubbard R., Farrington P., Smith C., Smeeth L., Tattersfield A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003, 158:77-84.
8. Bolton J.M., Metge C., Lix L., Prior H., Sareen J., Leslie W.D. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 2008, 28:384-391.
9. Ziere G., Dieleman J.P., van der Cammen T.J., Hofman A., Pols H.A., Stricker B.H. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008, 28:411-417.
10. Vestergaard P., Rejnmark L., Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 2008, 82:92-101.
11. Richards J.B., Papaioannou A., Adachi J.D., Joseph L., Whitson H.E., Prior J.C., et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007, 167:188-194.
12. van den Brand M.W., Pouwels S., Samson M.M., van Staa T.P., Thio B., Cooper C., et al. Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 2009, 20:1705-1713.
13. Thapa P.B., Gideon P., Cost T.W., Milam A.B., Ray W.A. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998, 339:875-882.
14. Warden S.J., Robling A.G., Sanders M.S., Bliziotes M.M., Turner C.H. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005, 146:685-693.
15. Haney E.M., Chan B.K., Diem S.J., Ensrud K.E., Cauley J.A., Barrett-Connor E., et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007, 167:1246-1251.
16. Warden S.J., Nelson I.R., Fuchs R.K., Bliziotes M.M., Turner C.H. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 2008, 15:1176-1183.
17. Westbroek I., van der Plas A., de Rooij K.E., Klein-Nulend J., Nijweide P.J. Expression of serotonin receptors in bone. J Biol Chem 2001, 276:28961-28968.
18. Bliziotes M.M., Eshleman A.J., Zhang X.W., Wiren K.M. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 2001, 29:477-486.
19. Battaglino R., Fu J., Spate U., Ersoy U., Joe M., Sedaghat L., et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004, 19:1420-1431.
20. Buurma H., Bouvy M.L., De Smet P.A., Floor-Schreudering A., Leufkens H.G., Egberts A.C. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 2008, 33:17-23.
21. WHO ATC/DDD Index 2008, World Health Organization collaborating centre for drug statistics methodology, Oslo.
22. Herings R.M., Stricker B.H., de Boer A., Bakker A., Sturmans F., Stergachis A. Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 1996, 49:115-119.
23. de Vries F., Pouwels S., Lammers J.W., Leufkens H.G., Bracke M., Cooper C., et al. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 2007, 261:170-177.
24. Warden S.J., Haney E.M. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies. J Musculoskelet Neuronal Interact 2008, 8:121-132.
25. Haney E.M., Warden S.J. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact 2008, 8:133-145.
26. Online reference (Ki data): Available at:http://pdsp.med.unc.edu. Accessed January 23, 2009.
27. Baldessarini R. Drugs and the treatment of psychiatric disorders. Depression and anxiety disorders. Goodman & Gilman's The pharmacological basis of therapeutics 2001, 456. McGraw-Hill, New York. A. Goodman (Ed.).
28. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997, 340:249-258.
29. Whooley M.A., Kip K.E., Cauley J.A., Ensrud K.E., Nevitt M.C., Browner W.S. Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999, 159:484-490.
30. Williams L.J., Pasco J.A., Jacka F.N., Henry M.J., Dodd S., Berk M. Depression and bone metabolism. Psychother Psychosom 2009, 78:16-25.
31. Cizza G., Primma S., Csako G. Depression as a risk factor for osteoporosis. Trends Endocrinol Metab 2009, 20:367-373.
32. Derijks H.J., Heerdink E.R., Janknegt R., de Koning F.H.P., Olivier B., Loonen A.J.M., et al. Visualizing pharmacological activities of antidepressants: a novel approach. Open Pharmacol J 2008, 2:54-62.
33. van Staa T.P., Dennison E.M., Leufkens H.G., Cooper C. Epidemiology of fractures in England and Wales. Bone 2001, 29:517-522.